ArticleOpen life sciences2026
Integrating bulk RNA-seq and ScRNA-seq to identify manganese metabolism-related subtypes and immunoregulatory mechanisms in liver hepatocellular carcinoma.
Article in Open life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver hepatocellular carcinoma (LIHC) is an aggressive cancer associated with chronic liver disease, necessitating better biomarkers and therapies. Manganese, an essential trace element, regulates tumor development. Data from TCGA and GEO databases were analyzed to identify manganese metabolism-related genes (MMRGs). LIHC samples were classified into subtypes via consensus clustering. A prognostic model was developed using LASSO and multivariate Cox regression, then validated using ROC and survival analysis. Immune infiltration was assessed via ssGSEA and CIBERSORT, and cell communication was analyzed with single-cell data (GSE149614). Tumor Mutational Burden (TMB), drug sensitivity, and a nomogram were also evaluated. Two manganese metabolism-related subtypes were identified, with Cluster 1 showing better survival. A two-gene model (CEP55 and SPP1) reliably predicted poor prognosis in high-risk groups. The high-risk group exhibited distinct immune profiles, including increased immune infiltration, elevated checkpoint expression, and higher TIDE scores. Single-cell analysis revealed altered T cell communication. This study established manganese metabolism-related subtypes and a prognostic model for LIHC, providing insights into immunoregulation and cell communication to guide precision diagnosis and immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.